Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

MDT-BRIDGE achieved an overall resection rate of 74.6% (95% CI 66.7–81.6) in resectable and borderline resectable non-small-cell lung cancer, including >1/3 borderline cases.

• Why it matters: The trial addresses how to deliver perioperative durvalumab plus neoadjuvant therapy while maintaining high resection and enabling curative-intent treatment when disease becomes unresectable.
• What they did: In this phase 2 study, patients received perioperative durvalumab with neoadjuvant chemotherapy (AEGEAN) and, if unresectable, chemoradiotherapy followed by consolidation durvalumab (PACIFIC) based on multidisciplinary team reassessment.
• The result: After neoadjuvant treatment, 131/142 (92.3%) received surgery (n=106) or CRT (n=25), and 117/142 (82.4%) received adjuvant or consolidation durvalumab with grade 3/4 adverse events of 7.4% and 17.4%, respectively.